The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF)
Status:
Enrolling by invitation
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This trial aims to investigate the impact of two target levels uric acid-lowering therapy
(ULT) caused by hyperuricemia (HU) on kidney function and CKD progression [1] measured by
eGFR and albuminuria (A) [2].
The main current tasks include 1) estimation serum uric acid (SUA) level most potential
preserving of kidney function 2) the new onset of gouts depending on SUA level, both in
gouts' and CKD' objects 3) safety and side effects of target and ultralow SUA levels for
evidence-based ULT optimal regime in CKD and non CKD with gout patients. 4) investigation of
cardio vascular rick ratio depending on SUA level.
The tasks also include
1. to determine U-curve or directly proportional relationship between SUA and eGFR-EPI in
CKD 1-4
2. to evaluate the new onset of goat which depends on SUA level and renal function In this
study the optimal ULT for kidney function based on target SUA level in 30 months'
treatment with either allopurinol or febuxostat will be determined.
Phase:
Phase 4
Details
Lead Sponsor:
Medical Practice Prof D. Ivanov
Collaborator:
Dr. T. Bevzenko, Dr. O. Synyachenko, Dr. I. Golovach